Related Experiment Videos
[Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis]
D Débat Zoguéreh1, J Boucraut, F Beau-Salinas
1Service de Neurologie, Centre Hospitalier Générale (CHG) Jacques Coeur, Bourges. david.debat_zoguereh@libertysurf.fr
Introduction:
Cutaneous tolerance of the interferon beta used in the treatment of relapsing-remitting multiple sclerosis is good. However, among the rare adverse effects, vasculitis and glomerular impairment have been described for interferon beta-1b.
Case Report:
A 36-year-old woman had been given subcutaneous injections of interferon beta 1-1a (Rebif, Serono) three times a week for ten weeks. A local transient cutaneous erythema was observed at the injection's sites. A few days after a new injection a erythematous plaques developed at the injection sites followed by pruritus, then purpura with edema on the leg in addition to an increase in body weight of 3 kg. Biological data showed proteinuria and hematuria. The histology study of skin specimens suggested non-specific lymphocytic vasculitis. Outcome was favorable after discontinuing interferon beta-1a.
Conclusion:
The etiology of the cutaneous and renal impairment is not formally established but the drug-induced hypothesis is proposed for interferon beta-1a.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Nephrotic Syndrome III : Nursing Management
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Nephrotic Syndrome I : Introduction
Multiple Sclerosis l: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention